CTIS2022-501474-19-00进行中（未招募）1 期
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations - DCC-3116-01-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 223
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •At least 18 years of age, Have progressed despite standard therapies, or for whom conventional therapy is not considered effective or tolerable, as judged by the Investigator, Must provide a fresh tumor biopsy from a primary or metastatic cancer lesion that can bebiopsied with acceptable risk as determined by the Investigator during the Screening Periodand an archival tumor tissue sample, if available (preferably collected after last anticancertherapy). If a fresh tumor biopsy is not possible, then an archival tumor tissue sample must be provided, Must have at least 1 measurable lesion according to RECIST v1.1, Eastern Cooperative Oncology Group (ECOG) performance status at Screening of 0 to 1
排除标准
- •Must not have received the following within the specified time periods prior to the first dose of study drug: a. Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp (refer to Section 9.8.3) including certain herbal medications (eg, St. John’s Wort): 14 days or 5× the half-life of the medication (whichever is longer) b. All other prior anticancer therapies or any therapy that is investigational for the participant’s condition with a known safety and PK profile: 14 days or 5× the half-life of the medication (whichever is shorter) c. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor’s Medical Monitor may approve a shorter washout of 14 days d. Grapefruit or grapefruit juice: 14 days, Have not recovered from all toxicities from prior therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 to Grade =1 or participant baseline prior to first dose of study drug (excluding alopecia).Participant baseline is defined as no change in severity grade within 28 days prior to signed informed consent, Presence or history of central nervous system (CNS) metastases or leptomeningeal disease, with the following exceptions: • If there is a history of brain metastases, they must be stable for at least 6 months (no new metastases and no evidence of progression of known metastases at Screening compared to historical scans) • If there is a history of leptomeningeal disease, it must have cleared at least 6 months prior to Screening • If there are neurologic symptoms consistent with CNS disease, they must not be new or increasing in severity over at least 6 months prior to Screening • If there is a history of CNS metastasis or leptomeningeal disease, it must not require continued therapy, New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug, Prolongation of the QT interval corrected by Fridericia’s formula (QTcF) based on repeated demonstration of QTcF >450 ms in males or >470 ms in females at Screening or history of long QT syndrome
研究者
相似试验
终止
1 期
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsAdvanced Solid TumorMetastatic Solid TumorNon-Small Cell Lung CancerNCT04892017Deciphera Pharmaceuticals, LLC91
招募中
1 期
A Phase 1, first in human study of DS-1055a in subjects with relapsed or refractory locally advanced or metastatic solid tumorslocally advanced or metastatic head and neck cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, or melanomaJPRN-jRCT2080225196DAIICHI SANKYO Co.,Ltd.40
终止
1 期
Phase I study of DS-2741a in Healthy Volunteers and Subjects with Atopic DermatitisHealthy volunteers and Japanese subjects with moderate to severe atopic dermatitis.JPRN-jRCT2080224983DAIICHI SANKYO Co., LTD.75
进行中（未招募）
1 期
A phase 1-2, first-in-human study of CX-2029 in adults with advanced solid tumors which cannot be removed completely through surgery, or cancer of B cells, a type of white blood cell responsible for producing antibodies.Metastatic or locally advanced unresectable solid tumor or diffuse large B-cell lymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061534Term: Oesophageal squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10041826Term: Squamous cell carcinoma of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001456-34-GBCytomX Therapeutics, Inc.150
进行中（未招募）
1 期
A phase 1-2, first-in-human study of CX-2029 in adults with advanced solid tumors which cannot be removed completely through surgery, or cancer of B cells, a type of white blood cell responsible for producing antibodies.EUCTR2018-001456-34-ESCytomX Therapeutics, Inc.202